Thomas C Wright, MD, World Recognized Women’s Health Sciences Authority, Joins Enzo Biochem’s Clinical Division

NEW YORK--(BUSINESS WIRE)-- Enzo Biochem, Inc. (NYSE:ENZ) announced today that Thomas C. Wright, MD, a leading authority in Women’s Health Diagnostics, has joined the Company as a Consulting Pathologist and Medical Advisor to the Company’s Women’s Health Initiative.

Dr. Wright is a leading expert in gynecological pathology in the U.S. He was the Director of the Division of Gynecologic, Perinatal, and Cytologic Pathology at Columbia University Medical Center and also directed the colposcopy services at New York Presbyterian Hospital for over 15 years. He is a Past President of the American Society of Colposcopy and Cervical Pathology and recipient of a number of awards.

Dr. Wright has published over 200 articles and chapters on gynecologic pathology and the diagnosis and treatment of cervical disease, in addition to sitting on the Editorial Boards of several well-known professional journals. He was the lead author of the 2001 and 2007 ASCCP Consensus Guidelines.

Dr. Wright currently is Professor Emeritus in Pathology and Cell Biology at Columbia University Medical Center in New York.

“We are extremely pleased that Dr. Wright has joined our scientific team,” said Elazar Rabbani, Ph.D., Enzo Biochem CEO. “In addition to his many academic achievements, Dr. Wright brings to our company invaluable experience in the diagnosis of women’s health diseases, which will directly benefit our core focus in this area.”

In his new role with Enzo, Dr. Wright will, among other responsibilities, develop and help organize the Company’s new Women’s Health Advisory Board, which will focus on both medical and diagnostic issues unique to this field, as well as deliver symposia on related topics to physician groups in the Company’s service areas. He will also oversee the review of the Company’s gynecologic pathology case load.

About Enzo Biochem

Enzo Biochem is a pioneer in molecular diagnostics, leading the convergence of clinical laboratories, life sciences and therapeutics through the development of unique diagnostic platform technologies that provide numerous advantages over previous standards. A global company, Enzo Biochem utilizes cross-functional teams to develop and deploy products systems and services that meet the ever-changing and rapidly growing needs of health care both today and into the future. Underpinning Enzo Biochem’s products and technologies is a broad and deep intellectual property portfolio, with patent coverage across a number of key enabling technologies

Except for historical information, the matters discussed in this news release may be considered "forward-looking" statements within the meaning of Section 27A of the Securities Act of 1933, as amended and Section 21E of the Securities Exchange Act of 1934, as amended. Such statements include declarations regarding the intent, belief or current expectations of the Company and its management, including those related to cash flow, gross margins, revenues, and expenses are dependent on a number of factors outside of the control of the company including, inter alia, the markets for the Company’s products and services, costs of goods and services, other expenses, government regulations, litigations, and general business conditions. See Risk Factors in the Company’s Form 10-K for the fiscal year ended July 31, 20123 Investors are cautioned that any such forward-looking statements are not guarantees of future performance and involve a number of risks and uncertainties that could materially affect actual results. The Company disclaims any obligations to update any forward-looking statement as a result of developments occurring after the date of this press release.

For Enzo Biochem, Inc.
Anreder & Company
Steven Anreder, 212-532-3232
steven.anreder@anreder.com
or
CEOcast, Inc.
Michael Wachs, 212-732-4300
mwachs@ceocast.com

Source: Enzo Biochem, Inc.

Released July 31, 2014